molecular

(redirected from molecularly)
Also found in: Dictionary, Thesaurus, Medical.

molecular

1. of or relating to molecules
2. Logic (of a sentence, formula, etc.) capable of analysis into atomic formulae of the appropriate kind
References in periodicals archive ?
According to Novartis Oncology Development and Medical Affairs global head Alessandro Riva, preclinical data suggests that combining molecularly targeted agents with immunotherapies such as nivolumab may have synergistic effects and lead to better outcomes for patients.
Through genetic engineering, scientists have created pigs that are extremely close molecularly to human beings, thereby reducing the risk of transferring a harmful disease.
The Mini-Rail Plane Rail family of linear guides features Frelon self-lubricating bearing material that is molecularly bonded to an aluminum carnage.
The simile is appropriate; glass is a super-cooled liquid - solid, yet molecularly amorphous.
Tumor Immunology: Molecularly Defined Antigens and Clinical Applications
Molecularly imprinted polymers are a source of robust artificial receptor sites.
A recent issue of Science magazine reported that scientists may eventually pin down a "minimum genome": the bare bones, molecularly speaking, of what it takes to make a living organism.
Each scope is coated with a nitride that is molecularly bonded to the titanium for maximum adhesion that will not blister, flake or chip.
Interviewed EU5 Payers Report that Well-Designed Cost-Sharing Schemes Are Also Increasingly a Prescribing Differentiator for Molecularly Targeted Agents, According to Findings from Decision Resources
CombiPlex combinations incorporating molecularly targeted agents show significant efficacy improvements over conventional targeted agent administration regimens -
Novartis announced today that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OpdivoA (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC).

Full browser ?